Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium-90-DOTA-M5A
- Development stage
- Phase 2
- Lead developer
- City of Hope
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
yttrium-90-DOTA-M5A is a radioimmunoconjugate composed of the humanized monoclonal antibody M5A, which targets carcinoembryonic antigen (CEA), conjugated to the radioactive isotope yttrium-90 via a DOTA chelator. The drug is designed for targeted radioimmunotherapy of CEA-expressing tumors, such as colorectal cancer and medullary thyroid cancer. By binding to CEA on tumor cells, it delivers cytotoxic radiation directly to malignant tissue while sparing normal cells. The humanized nature of the M5A antibody reduces immunogenicity compared with murine or chimeric antibodies, potentially allowing for repeated dosing. Developed initially by the National Cancer Institute, it has been evaluated in phase I/II clinical trials primarily for advanced metastatic cancers expressing CEA[1][2][4][6].
- Other names
- yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A90Y-DOTA-M5A
Beyond the preview
Go deeper on yttrium-90-DOTA-M5A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium-90-DOTA-M5A.